Introduction
Angioimmunoblastic T-cell lymphoma (AITL) is a distinct clinicopathological entity among peripheral T-cell lymphomas (PTCL) in the WHO classification, 1 usually characterized by generalized lymphadenopathy, hepatosplenomegaly, anemia and hypergammaglobulinemia. [2] [3] [4] Histologically, the lymph node architecture is partially effaced by a polymorphous T-cell infiltrate showing minimal cytological atypia and mixed with small reactive T cells, B immunoblasts, eosinophils, plasma cells, histiocytes, expanded follicular dendritic cells (FDCs) meshwork in T zones and abundant arborisation of endothelial venules. 1 In some cases, the histological diagnosis may be difficult as the morphology can overlap with a variety of reactive and neoplastic conditions such as auto-immune diseases, marginal zone lymphoma and more rarely classical Hodgkin's lymphoma. In these cases, the definitive diagnosis requires complementary immunological, cytogenetical and molecular data. Nevertheless, if a strong suspicion of T-cell malignancy can be supported by an aberrant pattern of T-cell antigens expression, such as the lack of CD3 expression, 5, 6 an abnormal pattern without specific markers does not allow by itself a precise subtyping. Interestingly, Attygalle et al. 7 recently reported that in this disorder a fraction of 5-30% of neoplastic T cells can be recognized by the aberrant expression of CD10 using immunohistochemistry. This specific phenotypic feature has been also confirmed in cell suspension of lymph nodes using two-colour flow cytometric (FCM) immunophenotyping in two of three AITL cases. 8 In the involved extranodal sites, the aberrant CD10 expression by T cells allows the diagnosis of AITL too. 9 Even if the precise diagnosis of AITL is achieved after biopsy and histological examination of one of the enlarged lymph nodes, the careful cytological analysis of peripheral blood smears could provide a valuable help in an early diagnosis before more invasive investigations, as usually performed in other lymphomas with blood dissemination, in particular small B-cell lymphoma. Nevertheless the peripheral blood dissemination of AITL has not yet been documented. 10 On the other hand, although the bone marrow is commonly described as involved, 1 the differential diagnosis with inflammatory process associating lymphoid cells, plasma cells and eosinophils is not always straightforward without complementary data. In this context, the analysis of peripheral blood may be particularly useful in the positive diagnosis of bone marrow involvement.
Here, we evaluated if AITL peripheral blood dissemination can be identified first by a rigorous peripheral blood smear analysis and secondly by CD10 detection on the potential circulating AITL T cells (with corresponding lymph node as positive control) using four-colour FCM immunophenotyping.
Materials and methods

Patients
In all, 12 cases diagnosed as AITL in our institution were integrated in the study and represented a consecutive series diagnosed between 1996 and 2004. The lymph node histology was reviewed and the diagnosis of AITL was confirmed in each case by a hemato-pathologist (FB) according to the WHO criteria. In 10 cases, peripheral blood smears (automatically prepared and May-Grü nwald Giemsa stained by Sysmex s SP-100 (Roche Diagnostics, Meylan, France) were evaluated for cytologic features including smear pattern and lymphoid cells characteristics.
In addition, lymph nodes (n ¼ 11), peripheral blood (n ¼ 6), bone marrow (n ¼ 1) and skin (n ¼ 1) samples were analyzed by flow cytometry. Some samples (n ¼ 7) have been conserved in fetal calf serum (FCS, Vysis, Voisins le Bretonneux, France) with 10% dimethyl sulfoxide (DMSO, Sigma, St Louis, USA) in liquid nitrogen until use.
Lymph nodes of reactive hyperplasia (n ¼ 14), follicular lymphoma (n ¼ 18), small lymphocytic lymphoma (n ¼ 6), mantle cell lymphoma (n ¼ 1), marginal zone lymphoma (n ¼ 5), diffuse large B cell lymphoma (n ¼ 2), Burkitt lymphoma (n ¼ 1), Hodgkin disease (n ¼ 1), unspecified peripheral T-cell lymphoma (n ¼ 6) as well as peripheral blood from T cell large granular lymphocytic leukaemia (n ¼ 5), Sezary syndrome (n ¼ 2), unspecified peripheral T-cell lymphoma (n ¼ 11), healthy donors (n ¼ 10) and reactive conditions (n ¼ 18) were used as a control group (lymph node, n ¼ 54; peripheral blood, n ¼ 46).
Flow cytometry
Fresh or thawed lymph node suspensions and whole peripheral blood samples were stained using three-or four-combinations of monoclonal antibodies directly conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), phycoerythrin-Texas Red s (ECD) or phycoerythrin-Cyanin 5 (PC5). The following monoclonal antibodies were used: CD2-FITC (clone T11)*, CD3-ECD (clone UCHT1)*, CD4-FITC (clone 13B8.2)*, CD5-PC5 (clone BL1A)*, CD7-PE (clone 3A1E-12H7)*, CD8-PE (clone B9.11)* and CD10-PE (clone HI10a)**, CD19-ECD (clone J4.119)*(*Beckman-Coulter, Hialeah, FL, USA and **Becton Dickinson, San Jose, CA, USA). Briefly, 0.5-1 Â 10 6 cells/tube were incubated at room temperature for whole blood and at 41C for lymph node suspensions for 15 min in the dark with saturating amounts of monoclonal antibodies. For blood samples, after incubation, erythrocytes were lysed manually using erythrocyte lysing reagent (Uti-Lyse, Dako, Carpinteria, CA, USA). Then, cells were washed in phosphate-buffered saline (PBS)/FCS (10%) and resuspended in PBS for acquisition. The cell viability was assessed by Trypan blue (Sigma) exclusion assay.
Samples were analyzed on a Coulter EPICS XL flow cytometer (Expo32 ADC software, Beckman-Coulter), which was daily calibrated with flow-Check fluorospheres (Beckman-Coulter). For each sample, isotype-matched negative controls conjugated to each fluorochrome were used to set the location of the cursor. 
Immunohistochemical study
Immunological characterization of AITL cases was performed on formalin-fixed paraffin-embedded tissues sections. An antigen retrieval method was used before an avidin-biotin complex immunoperoxidase technique on an automated immunostainer (NEXES Ventana Medical System) according to the manufacturer's instructions. An immunohistochemical panel including B-cell (L26/CD20:Dako), T cell (polyclonal CD3:Dako), FDCs (clone CNA42:Dako) markers and monoclonal antibodies against CD10 (clone J6C56:Novacastra, Newcastle, UK) was used. Appropriate positive and negative controls were run for each antibody. In situ hybridization for EBV-encoded mRNA (EBER) was performed using the Dako EBV probe kit following the manufacturer's protocol.
Molecular study
DNA was extracted from tissue or cell suspensions using High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany). T-cell receptor (TCR) g-chain gene rearrangements were studied by using a GC-clamp multiplex PCR-g-DGGE procedure as previously described 11 and the immunoglobulin (Ig) gene rearrangements by multiplex PCR using consensus primers from European BIOMED-2 concerted action. 12 
Results
Clinical and biological data
The patients (six men and six women) ranged in age from 38 to 82 years (median 58 years). Most patients presented with generalized lymphadenopathy (eight of 12 cases) and detailed clinical data are summarized in Table 1 .
Laboratory investigations showed anaemia in all cases. A hypergammaglobulinemia was present in six cases, hypogammaglobulinemia in four cases and one case presented a normal immunoglobulin profile. In two cases, a monoclonalcomponent (IgG kappa) was found in the serum, one case with hypogammaglobulinemia and one with hypergammaglobulinemia. At the time of lymph node biopsy, a lymphopenia (lymphocyte o1.00 Â 10 9 /l) was present in eight of 12 cases and four cases presented a normal value of lymphocytes (mean 1.38 Â 10 9 /l (range 1.10-3.37)). In two cases, an increased lymphocytosis (6.10 Â 10 9 /l and 11.32 Â 10 9 /l) was observed 5 months (case no. 5 0 ) and 1 year (case no. 6 0 ) after the diagnosis, respectively ( Table 1) .
The bone marrow (biopsy and smears) was infiltrated by lymphoma cells in nine of 11 available cases (five of them studied in peripheral blood).
Cytological analysis of peripheral blood smears
In all available cases but one, cytological analysis of peripheral blood smears showed a polymorphic lymphoid population containing a minority of atypical lymphocytes (10-20%) admixed with a majority of small lymphocytes, large granular lymphocytes, lymphoplasmacytic cells and sometimes plasma cells. In one case with hyperlymphocytosis (case no. 6 0 ), the lymphoid population was composed mainly of atypical lymphocytes (90%). Atypical cells (Figure 1 ), small to large-sized, presented regular nuclei or occasionally discrete indentations and a moderately condensed but not clumped chromatin. Nucleoli were usually small or indistinct. The cytoplasm was moderately abundant with variable basophilia (faint to moderate), sometimes with micro-vacuoles and without azurophilic granules. A pronounced rouleaux-formation was present in all cases with hypergammaglobulinemia or monoclonal component. No apoptotic features were noted in the six peripheral blood smears.
Immunology
Multiparameter flow cytometric immunophenotyping. . Given that the CD3 surface antigen appears as the most frequently down-regulated or absent pan-T antigen in PTCL 13, 14 and particularly in AITL, 8, 15 we chose to gate T cells population using the anti-CD4 and anti-CD5 monoclonal antibodies combination rather than the usual anti-CD3 antibody. Thus in addition to the routine panel of lymphoma diagnosis, the quadruple staining with CD4/CD10/CD19/CD5 was performed in all samples to evaluate the expression of CD10 by T cells.
Circulating neoplastic CD10 positive T cells in AITL L Baseggio et al
First, the effect of cryopreservation and thawing on CD10 expression by B-and T cells was evaluated on several thawed samples (follicular lymphomas, reactive hyperplasias, mature T-cell lymphomas) that had been cryopreserved for up to 9 years. The CD10 expression was not modified by cryopreservation and thawing (data not shown).
In 10/11 AITL lymph nodes, a fraction of T cells coexpressed CD10 with a mean percentage of 17% (range 5.00-58.00%) ( Table 2 ) and high fluorescence intensity (mean of CD10 MFI ¼ 8.00 (range 4.70-18.50). These CD10 T cells formed a distinct population in flow cytometric histograms and dot plot ( Figure 2) . Interestingly, among these 11 cases, six could be also studied in peripheral blood and all cases showed a fraction of T-cells expressing CD10 with a mean percentage of 18.75% (range 5.00-47.00%) ( Table 2 ) and high intensity (mean of CD10 MFI ¼ 11.00 (range 3.20-43.80). Circulating CD10 positive T cells were found independently of the lymphocyte value: while two cases presented hyper-lymphocytosis and obvious atypical lymphocytes, two cases presented a lymphopenia and two cases a normal lymphocyte value. On the other hand, the percentage of circulating CD10 T cells did not appear to correlate with the lymphocytosis: a low percentage of CD10 T cells could be find in nonlymphopenic patient (case no. 6 0 ) while a high percentage could be find in lymphopenic patients (case no. 8 0 ). Although only three pairs of samples were examined at the same time, the fraction of CD10 T cells was practically similar in lymph node and blood samples. In two cases of AITL previously diagnosed in lymph nodes, an aberrant CD10 expression by T cells (5 and 8% of all CD5 positive T cells) was found in bone marrow and skin nodule, respectively (Table 2, cases no. 10 and no. 3a). In contrast, T cells were CD10 negative in the control group particularly in all peripheral blood samples using the cutoff of 5%. However, a discrete fraction of CD10 positive T cells (mean percentage of 2% of all In our series, all presumed tumoral T cells were CD4 positive, except one case that showed CD4/CD8 double negative phenotype. In three cases of lymph nodes and corresponding peripheral blood, presumed tumoral T cells presented a complete loss of surface CD3 antigen but with expression of cytoplasmic CD3 antigen. In all nodal cases, pan-T cell markers CD7, CD5 and CD2 were always positive in CD10 T cells but with lower expression in comparison with normal T cells in 3, 1 and 1 cases, respectively (Table 2) . In all peripheral blood samples but one, tumor T cells showed the same immunological pattern than in lymph nodes sample. In this last case, the CD7 expression was weaker in peripheral blood than in lymph nodes sample.
In summary, among all lymph node cases, CD2 and CD5 were the least commonly downregulated antigen (n ¼ 1), the other pan-T antigens were aberrantly lacking (CD3, n ¼ 3) or diminished (CD7, n ¼ 3). The immunological pattern was identical in all corresponding peripheral blood samples. Presumed neoplastic T cells expressed CD10 in 10/11 of lymph nodes, 2/2 of extra-nodal sites and 6/6 peripheral blood samples.
Immunohistochemistry. In all cases of lymph node biopsies but one, a population of CD10 positive lymphoid cells was diffusely distributed outside the follicles in addition to CD10 positive germinal center cells (Table 3, Figure 3 ). After careful comparison with morphology and CD3 and CD20 immunostaining, these CD10 positive lymphoid cells were considered to be neoplastic T cells. These CD10 stainings confirmed the results obtained in FCM analysis. Indeed, the cases with numerous CD10 positive T cells in T-zone on lymph node sections presented the highest percent of CD10 positive T cells in lymph node suspensions. Expanded FDCs meshwork was observed in CD3 T-cell area in all cases but one (Table 3, Figure 3 ). Aberrant CD10 expression correlated well with the interfollicular distribution of FDCs, since the unique CD10 negative case presented few FDC meshwork outside follicles.
TCR-g and IgH rearrangement
All cases but one presented a monoclonal T-cell population (Table 4 ). In the three cases where peripheral blood and lymph nodes were studied concomitantly, an identical TCR gene rearrangement was found. Four of nine available samples also showed a minor B-cell clone. All cases with B-cell clone presented a normal or low T-cell/B-cell ratio, whereas cases with polyclonal B-cells had an increased T-cell/B-cell ratio.
Discussion
The present report supports previous studies indicating that the CD10 antigen is expressed by a fraction of neoplastic T cells in lymph nodes from patients with AITL using immunohistochemistry 7, 16, 17 or FCM analysis. 8 Moreover, it constitutes the first study demonstrating peripheral blood involvement by a fraction of CD10 positive presumed neoplastic T cells in AITL patients. In addition, we suggest that these tumoral T cells may be identified by a careful analysis of peripheral blood smears, since in our series 10-20% of the whole lymphoid population were atypical. Thus in a context of generalized lymphadenopathy, the association of lymphopenia with a polymorphous lymphoid cell population of small lymphocytes, lymphoplasmacytic and plasma cells is suggestive of AITL dissemination and must lead to a careful search for atypical lymphoid cells and to FCM immunophenotyping for CD10 positive T cells.
In the present study, the expression of CD10 by T cells was found in 10 of 11 lymph nodes suspension (91%) and in all analyzed extra-nodal sites (one bone marrow and one skin sample) in agreement with previous studies. 7, 9 Interestingly, the aberrant CD10 expression and immunological pattern of some circulating T lymphocytes, identical to that of the diagnostic lymph node obtained by biopsy, point to the fact that neoplastic T cells are present in all analyzed peripheral blood, even if lymphocyte values are normal or below normal. This was 
Circulating neoplastic CD10 positive T cells in AITL L Baseggio et al confirmed by molecular biology showing identical TCR gene rearrangements in peripheral blood and lymph nodes in three cases concurrently analyzed. Thus neoplastic T cells of AITL may disseminate in peripheral blood as previously suggested by the presence of surface CD3 negative/CD4 positive neoplastic T cells in peripheral blood of AITL patients 15 and these cells may be more specifically identified by the CD10 expression.
A double staining appears necessary to identify the CD10 expression by T cells, since the CD10 may be expressed by different cells such as B cells of the germinal centers, granulocytes, B cells of follicular lymphoma and a subset of diffuse large B-cell lymphoma. 19 On biopsy section, the double immuno-staining using CD3/CD10 or CD20/CD10 may be difficult to interpret when normal or hyperplastic germinal center are present and/or when the T-clone constitutes a minor population. In contrast, the CD10 antigen is detected by FCM simultaneously with other T-cell and B-cell markers in quadruple staining allowing a specific gate to the different populations and the identification of a small but phenotypically distinct T-cell population. As tumoral T cells tend to down-regulate the expression of a number of surface molecules in particular the CD3 or CD7, 13 the most suitable pan-T antigen seems to be CD5 in combination with CD4 since AITL derive from CD4 positive T cells in the majority of cases. 20 On the other hand, the representativity of lymph node suspensions analysed by FCM may be questionable since only a fraction of T cells was shown to express CD10 on biopsy sections. Nevertheless, in the present study, the CD10 positivity in FCM analysis correlates closely with the results obtained in immunohistochemistry. More importantly, the circulating CD10 positive T cells were identified in peripheral blood using fourcolour FCM even if the neoplastic CD10 T cells in lymph nodes were rare.
The definition of a positive cutoff in FCM appears essential since Cook et al. 21 has reported that a fraction (mean 7%, range 3-14%) of benign T cells may express the CD10 antigen in 23% of follicular lymphoma, 18% of reactive hyperplasia and 47% of marginal zone lymphoma. According to previous studies in AITL lymph node specimens using immunohistochemistry 7 or FCM, 8 where CD10 positive neoplastic T cells represent a small proportion of T cells (5-30 and 5-7%, respectively), a positive CD10 cutoff was set at 5% of all CD5 T cells in our study. With this positive cut off, none of the case from the control groups (other T cell lymphomas, B-cell lymphoma, reactive conditions and healthy donors) was considered as positive, in agreement with previous results. [7] [8] [9] The discrepancy between these results and Cook's study could be explained by some technical issues such as the use of different anti-CD10 clones and the sensitivity of each individual method. Moreover, when T cells have an aberrant immunological profile such as loss of CD3 antigen or downexpression of one pan-T antigen, a threshold of CD10 expression by abnormal T cells below 5% could probably be considered as a specific marker pointing to the diagnosis of AITL.
The assessment of CD10 expression by T cells using multiparameter FCM analysis with imperative cutoff of positivity seems highly sensitive and specific of AITL. The detection of CD10 positive T cells may thus constitute an important argument for the diagnosis of AITL and a helpful tool for the affirmation of bone marrow involvement rather than an inflammatory process. In addition, the detection of CD10 positive T cells in blood may also be useful for tracking minimal residual disease in this lymphoma.
The physiologic role of CD10 expression by neoplastic T cells is still unknown. CD10 has been characterized as the neutral endopeptidase 24.11 and appears to play a functional role in promoting early T 22 and B cell 23 development as well as in regulating tumor T cell proliferation 24 and more recently in the regulation of the apoptotic process in T and B cells. 25, 26 Cutrona et al. 25 reported indeed that apoptotic T cells expressed CD10 and showed decreased CD3 expression. Thus, the aberrant CD10 expression in neoplastic T cells in AITL may be an indicator of disturbed apoptotic cell death. However, apoptosis is not described as a relevant feature in AITL. In the present series, no apoptotic cells were cytologically identified on peripheral blood samples. On the other hand, the close correlation between the aberrant CD10 expression by T cells and the distribution of FDCs argues strongly for a role of FDCs in triggering this abnormal expression. 9 This hypothesis is also supported by the observation that follicular microenvironement induced by FasL-expressing FDC in AITL may cause the neoplastic T cells to upregulate CD10 expression. 16 In our series, the single CD10 negative case showed only rare FDCs outside the follicles. Thus, these observations provide supplementary arguments to the specificity of CD10 expression by T cells in the diagnosis of AITL.
In conclusion, we document that the peripheral blood dissemination of AITL lymphoma cells appears as more frequent than previously described, 10 since six of six studied peripheral blood samples showed CD10 circulating presumed neoplastic T cells whatever be the percent of CD10 T cells in lymph nodes. Nevertheless their detection need to be evaluated in a larger series in order to assess the true incidence of blood dissemination in AITL and its relevant contribution to the affirmation of malignancy, to the precise subtype of lymphoma and to the detection of bone marrow involvement.
